Sort
48,018 grants matching “immunotherapy”
Structure, Function and Mechanistic Analysis of LAG3
$726,102Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · AI
Passive immunotherapy using plant-derived broadly HIV-1 neutralizing MAbs to prev
$726,046Yvonne J Rosenberg · Plantvax, Inc. · R44 · FY2011 · AI
Defining the CD4 T Cell Response to Immunization with GAD
$726,039Helena Kristiina Reijonen · Benaroya Research Inst At Virginia Mason · DP3 · FY2012 · DK
HBV-specific T cell immunity in HBV/HIV coinfection
$725,950Michael Jeffrey Vinikoor · University Of Alabama At Birmingham · R37 · FY2024 · AI
Targeting virus-specific CAR T cells to lymphoid follicles to achieve durable HIV suppression
$725,949Pamela J Skinner · University Of Minnesota · R01 · FY2020 · AI
Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer
$725,640Stephen B Gruber · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
PROJECT 2: Development and Refinement of Predictive Models for Designing Immunotherapy Combination Treatments
$725,549Vesteinn Thorsson · Institute For Systems Biology · U54 · FY2023 · CA
Tissue ProcessingSequencing Core
$725,535Cathy D Vocke · Division Of Basic Sciences - Nci · ZIC · FY2010 · CA
Preclinical development of breakthrough immunotherapy for brain tumors
$725,326Hideho Okada · University Of California, San Francisco · R35 · FY2023 · NS
Preclinical development of breakthrough immunotherapy for brain tumors
$725,326Hideho Okada · University Of California, San Francisco · R35 · FY2022 · NS
Preclinical development of breakthrough immunotherapy for brain tumors
$725,326Hideho Okada · University Of California, San Francisco · R35 · FY2021 · NS
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
$725,319Michael Karin · University Of California, San Diego · U01 · FY2021 · AA
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
$725,319Michael Karin · University Of California, San Diego · U01 · FY2022 · AA
Macaque Models of AIDS-Related Tuberculosis and T Cell
$725,199University Of Illinois At Chicago · R01 · FY2004 · HL
Reprogramming intestinal immunity in preterm neonates to prevent and cure necrotizing enterocolitis
$725,129Misty L Good · Univ Of North Carolina Chapel Hill · DP1 · FY2025 · DK
Reprogramming intestinal immunity in preterm neonates to prevent and cure necrotizing enterocolitis
$725,077Misty L Good · Univ Of North Carolina Chapel Hill · DP1 · FY2024 · DK
Immunotherapy for Malignant Mesothelioma
$725,065Raffit Hassan · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
MATCHMAKERS - Creating and training AI tools for TCR binding prediction and design
$725,052Michael Birnbaum · Massachusetts Institute Of Technology · OT2 · FY2025 · CA
Molecular Genetic Analysis of Mycobacterium tuberculosis
$724,867William Robert Jacobs · Albert Einstein College Of Medicine · R01 · FY2014 · AI
Novel Cellular Therapies for Ph+ leukemia
$724,784Richard A. Van Etten · Tufts Medical Center · R01 · FY2010 · HL
Immune Response to RBC Antigens
$724,646Krystalyn E Hudson · Columbia University Health Sciences · R01 · FY2023 · HL
T CELL AUTOIMMUNITY
$724,526Washington University · P01 · FY2000 · AI
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
$724,384Michael Karin · University Of California, San Diego · U01 · FY2020 · AA
Immunosuppressive mechanisms responsible for development of non-viral liver cancer and control of its response to immune checkpoint inhibitors
$724,197Michael Karin · University Of California, San Diego · U01 · FY2019 · AA
Project 1 - Evolutionary and ecological dynamics of tumor-host interactions
$724,120Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2016 · CA